Abstract
Routine testing for prostatic carcinoma by digital rectal examination, transrectal ultrasonography and prostate specific antigen determination has been proposed to reduce deaths by earlier diagnosis. The questionable reliability of results, cost of screening, and inability to establish a balance between the benefits of treatment and the adverse effects on the quality of life of the men screened make screening experimental until controlled studies prove its value.